Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report released on Monday morning. The brokerage issued a hold rating on the stock.

Several other analysts also recently weighed in on ONCT. Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Northland Securities reissued a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Finally, Northland Capmk downgraded Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.00.

Oncternal Therapeutics Stock Performance

NASDAQ ONCT opened at $0.53 on Monday. The company has a market capitalization of $1.56 million, a PE ratio of -0.05 and a beta of 1.18. The stock has a 50-day simple moving average of $0.81 and a 200 day simple moving average of $3.00. Oncternal Therapeutics has a 12 month low of $0.53 and a 12 month high of $13.14.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.